GU Cancers 2024 | PAPMET2: cabozantinib with or without atezolizumab in PRCC

Benjamin Maughan, MD, PharmD, University of Utah, Salt Lake City, UT, gives an overview of the Phase II PAPMET2 trial (NCT05411081) of cabozantinib alone versus cabozantinib with atezolizumab in patients with advanced papillary renal cell carcinoma (PRCC). The primary endpoint is progression-free survival (PFS), and the trial will build upon existing data assessing TKI inhibitors with immune checkpoint inhibitors in this space. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.